FDA to hold public hearings on CBD in April
Food and Drug Administration (FDA) will hold public hearings on CBD in April, according to statements made by FDA Commissioner Scott Gottlieb, during a recent House Appropriations subcommittee hearing. The purpose of the public hearing will be to start the rule-making process and gather stakeholder input on how the FDA can regulate hemp-derived CBD.
In addition, FDA will form a working group of senior officials and agency experts to advise the Commissioner on regulatory options. Gottlieb affirmed Congress wants a path for regulating food and dietary supplements containing CBD. Gottlieb said, “this is not a straightforward process. There’s not a good proxy for us doing this through regulation.”
The conceptual regulatory framework includes a pharmaceutical path and a path for food products and dietary supplements. Gottlieb specifically mentions FDA approved CBD epilepsy medication, Epidiolex and wanting to maintain a motivation to study CBD for pharmaceutical products by keeping a pharmaceutical regulatory framework.
Although Gottlieb declared his attention to the complexities of regulating CBD, he recently announced his April resignation for personal reasons, almost a year after his appointment as FDA Commissioner.
McAllister Garfield, P.C. is busy advising hemp and CBD companies during this time of transition. For more information, contact McAllister Garfield today.
Related Article
Psychedelic Therapy & Law Update – April 2026
President Trump to Issue Executive Order on Ibogaine President Trump will sign an executive order opening doors for more federal reserach on ibogaine, the naturally occuring psychedelic substance with indigenous roots in Africa. For more information, see this article by clicking here. Ibogaine has shown significant benefits for veterans suffering from war trauma, those suffering from […]
Psychedelic Therapy & Law Update – March 2026
Colorado starts the rulemaking process again for NMHA program changes DOR Natural Medicine Division is proposing several rules changes to the NMHA rules. These proposed changes include a significant increase in the cost of standard healing center licenses (from $6k to over $10k). Other proposed changes include adding an owner entity fee, prohibiting cultivator sampling […]
Psychedelic Therapy & Law Update – February 2026
Maryland and New Jersey moving toward creation of psilocybin programs The Maryland Task Force on Responsible Use of Natural Psychedelic Substances, in a report near the end of 2025 endorsed the creation of a regulated psilocybin program in the state. The recommendation still needs to be adopted by the Maryland legislature, but this is an […]